2016-08-01 14:44:47 UTC

Update on the Safety Profile of Nonselective Beta Blockers

Aug. 2, 2016

CGH meta-analysis finds that NSBBs do not increase mortality in patients with cirrhosis and ascites or refractory ascites.

Nonselective beta blockers (NSBBs) do not significantly increase the risk of death in patients with cirrhosis and ascites or refractory ascites, researchers report in the August issue of Clinical Gastroenterology and Hepatology (CGH). The findings from this meta-analysis do not support the position that NSBBs be routinely withheld from patients with ascites.

The researchers performed a meta-analysis of data from studies of NSBBs to determine whether they are more likely to harm or help patients with cirrhosis. The authors found that use of NSBBs was not associated with increased all-cause mortality. Similar findings were made for patients with nonrefractory ascites or refractory ascites.

Read more about this CGH study on the AGA Journals Blog

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Oct. 1, 2017

Among HCV-infected patients treated with DAAs, SVR is associated with a considerable reduction in the risk of HCC; however, the risk for HCC remained high in patients with cirrhosis at the time of SVR.